PTX - Pernix Therapeutics Holdings, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue140,856175,850121,747
Cost of Revenue43,32051,40847,965
Gross Profit97,536124,44273,782
Operating Expenses
Research Development6,0798,2293,938
Selling General and Administrative143,360121,63567,059
Non Recurring2,2871,1371,137
Total Operating Expenses237,864225,696-
Operating Income or Loss-140,328-101,254-30,214
Income from Continuing Operations
Total Other Income/Expenses Net9,034-1,722353
Earnings Before Interest and Taxes-131,294-102,976-29,861
Interest Expense37,85738,27719,150
Income Before Tax-169,151-141,253-49,011
Income Tax Expense4397,062-13,725
Minority Interest---
Net Income From Continuing Ops-169,590-148,315-35,286
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-169,590-148,315-35,286
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-169,590-148,315-35,286